Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
BriaCell to host conference call » 09:37
06/16/21
06/16
09:37
06/16/21
09:37
BCTX

BriaCell

$6.03 /

+0.51 (+9.24%)

CEO Williams holds a…

CEO Williams holds a corporate and clinical update conference call on June 16 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
BCTX BriaCell
$6.03 /

+0.51 (+9.24%)

  • 24
    Feb
Hot Stocks
Atossa Therapeutics set to join Russell 2000, Russell 3000 Indexes » 09:07
06/16/21
06/16
09:07
06/16/21
09:07
ATOS

Atossa Therapeutics

$4.61 /

-0.02 (-0.43%)

Atossa Therapeutics…

Atossa Therapeutics announced it is set to be added to the Russell 2000 and Russell 3000 Indexes. This will take place at the conclusion of the 2021 Russell Indexes' annual reconstitution, effective after the U.S. market opens on June 28, 2021, according to a preliminary list of additions posted June 4, and June 14, 2021.

ShowHide Related Items >><<
ATOS Atossa Therapeutics
$4.61 /

-0.02 (-0.43%)

ATOS Atossa Therapeutics
$4.61 /

-0.02 (-0.43%)

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
ATOS Atossa Therapeutics
$4.61 /

-0.02 (-0.43%)

ATOS Atossa Therapeutics
$4.61 /

-0.02 (-0.43%)

On The Fly
Fly Intel: Pre-market Movers » 08:53
06/16/21
06/16
08:53
06/16/21
08:53
SPI

SPI Energy

$6.57 /

-0.19 (-2.81%)

, KIN

Kindred Biosciences

$6.35 /

+0.31 (+5.13%)

, ELAN

Elanco

$34.83 /

+1.33 (+3.97%)

, MNKD

MannKind

$4.11 /

-0.02 (-0.48%)

, ARVL

Arrival

$19.90 /

+1.14 (+6.08%)

, FORD

Forward Industries

$2.73 /

-0.15 (-5.21%)

, CNTG

Centogene

$10.25 /

-0.31 (-2.94%)

, ORCL

Oracle

$81.64 /

-0.95 (-1.15%)

, MX

MagnaChip

$25.64 /

-0.2 (-0.77%)

, BNTX

BioNTech

$217.98 /

-2 (-0.91%)

, IKT

Inhibikase Therapeutics

$4.03 /

-0.825 (-16.99%)

, RBLX

Roblox

$89.80 /

+2.02 (+2.30%)

Check out this morning's…

ShowHide Related Items >><<
SPI SPI Energy
$6.57 /

-0.19 (-2.81%)

RBLX Roblox
$89.80 /

+2.02 (+2.30%)

ORCL Oracle
$81.64 /

-0.95 (-1.15%)

MX MagnaChip
$25.64 /

-0.2 (-0.77%)

MNKD MannKind
$4.11 /

-0.02 (-0.48%)

KIN Kindred Biosciences
$6.35 /

+0.31 (+5.13%)

IKT Inhibikase Therapeutics
$4.03 /

-0.825 (-16.99%)

FORD Forward Industries
$2.73 /

-0.15 (-5.21%)

CNTG Centogene
$10.25 /

-0.31 (-2.94%)

BNTX BioNTech
$217.98 /

-2 (-0.91%)

ARVL Arrival
$19.90 /

+1.14 (+6.08%)

SPI SPI Energy
$6.57 /

-0.19 (-2.81%)

KIN Kindred Biosciences
$6.35 /

+0.31 (+5.13%)

05/12/21 Alliance Global Partners
Kindred Biosciences price target raised to $15.25 from $9.25 at Alliance Global
12/24/20 Barclays
Kindred atopic dermatitis portfolio could net $130M in sales, says Barclays
12/18/20 Alliance Global Partners
Kindred Biosciences price target lowered to $9.25 from $10.25 at Alliance Global Partners
12/14/20 Lake Street
Kindred Biosciences struck 'terrific arrangement' with Elanco, says Lake Street
ELAN Elanco
$34.83 /

+1.33 (+3.97%)

06/15/21 Cleveland Research
Elanco upgraded to Neutral from Underperform at Cleveland Research
05/17/21 Citi
Elanco price target raised to $42 from $39 at Citi
05/11/21 Gabelli
Elanco upgraded to Buy from Hold at Gabelli
05/11/21 Barclays
Elanco upgraded to Equal Weight from Underweight at Barclays
MNKD MannKind
$4.11 /

-0.02 (-0.48%)

05/13/21 RBC Capital
MannKind initiated with a Sector Perform at RBC Capital
02/26/21 H.C. Wainwright
MannKind price target raised to $6.50 from $2.50 at H.C. Wainwright
02/24/21 BTIG
MannKind price target raised to $8 from $4 at BTIG
12/29/20 BTIG
United Therapeutics' treprostinil development uses MannKind technology, say BTIG
ARVL Arrival
$19.90 /

+1.14 (+6.08%)

06/03/21 Barclays
Arrival initiated with an Overweight at Barclays
04/05/21 Cowen
Cowen starts Arrival at Outperform on 'unique microfactory approach'
04/05/21 Cowen
Arrival initiated with an Outperform at Cowen
FORD Forward Industries
$2.73 /

-0.15 (-5.21%)

CNTG Centogene
$10.25 /

-0.31 (-2.94%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
ORCL Oracle
$81.64 /

-0.95 (-1.15%)

08:50 Today Morgan Stanley
Oracle shares likely range-bound until visibility improves, says Morgan Stanley
08:27 Today Jefferies
Oracle price target raised to $80 from $75 at Jefferies
07:57 Today Monness Crespi
Monness Crespi would be buyers of Oracle on any post-earnings weakness
07:35 Today JPMorgan
Oracle price target raised to $77 from $73 at JPMorgan
MX MagnaChip
$25.64 /

-0.2 (-0.77%)

03/30/21 Vertical Group
MagnaChip downgraded to Neutral from Buy at Vertical Group
03/04/21 Needham
Needham revises view on MagnaChip SOTP value to $41-$46 per share
03/04/21 Needham
MagnaChip could be worth $39-$45 per share in a deal, says Needham
02/23/21 Citi
MagnaChip price target raised to $20 from $19 at Citi
BNTX BioNTech
$217.98 /

-2 (-0.91%)

05:05 Today Redburn
BioNTech downgraded to Sell from Neutral at Redburn
05/18/21
Fly Intel: Top five analyst initiations
05/18/21 Goldman Sachs
BioNTech initiated with a Neutral at Goldman Sachs
05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
IKT Inhibikase Therapeutics
$4.03 /

-0.825 (-16.99%)

04/26/21 ThinkEquity
Inhibikase Therapeutics initiated with a Buy at ThinkEquity
RBLX Roblox
$89.80 /

+2.02 (+2.30%)

07:17 Today Morgan Stanley
Morgan Stanley lowers Q2 estimates for Roblox, says long-term view unchanged
07:10 Today JPMorgan
Roblox shares likely range-bound after May metrics, says JPMorgan
07:04 Today Stifel
Roblox May KPIs 'probably not enough' to sustain shares' momentum, says Stifel
06/01/21 Truist
Roblox price target raised to $103 from $83 at Truist
RBLX Roblox
$89.80 /

+2.02 (+2.30%)

ORCL Oracle
$81.64 /

-0.95 (-1.15%)

MX MagnaChip
$25.64 /

-0.2 (-0.77%)

MNKD MannKind
$4.11 /

-0.02 (-0.48%)

KIN Kindred Biosciences
$6.35 /

+0.31 (+5.13%)

ELAN Elanco
$34.83 /

+1.33 (+3.97%)

CNTG Centogene
$10.25 /

-0.31 (-2.94%)

BNTX BioNTech
$217.98 /

-2 (-0.91%)

  • 16
    Jun
  • 01
    Dec
  • 28
    Oct
  • 01
    Oct
  • 23
    Jul
  • 10
    Jul
RBLX Roblox
$89.80 /

+2.02 (+2.30%)

ORCL Oracle
$81.64 /

-0.95 (-1.15%)

ELAN Elanco
$34.83 /

+1.33 (+3.97%)

BNTX BioNTech
$217.98 /

-2 (-0.91%)

ARVL Arrival
$19.90 /

+1.14 (+6.08%)

SPI SPI Energy
$6.57 /

-0.19 (-2.81%)

RBLX Roblox
$89.80 /

+2.02 (+2.30%)

ORCL Oracle
$81.64 /

-0.95 (-1.15%)

MX MagnaChip
$25.64 /

-0.2 (-0.77%)

KIN Kindred Biosciences
$6.35 /

+0.31 (+5.13%)

IKT Inhibikase Therapeutics
$4.03 /

-0.825 (-16.99%)

FORD Forward Industries
$2.73 /

-0.15 (-5.21%)

ELAN Elanco
$34.83 /

+1.33 (+3.97%)

BNTX BioNTech
$217.98 /

-2 (-0.91%)

ARVL Arrival
$19.90 /

+1.14 (+6.08%)

SPI SPI Energy
$6.57 /

-0.19 (-2.81%)

RBLX Roblox
$89.80 /

+2.02 (+2.30%)

ORCL Oracle
$81.64 /

-0.95 (-1.15%)

MNKD MannKind
$4.11 /

-0.02 (-0.48%)

BNTX BioNTech
$217.98 /

-2 (-0.91%)

ARVL Arrival
$19.90 /

+1.14 (+6.08%)

Hot Stocks
Bioceres collaborating with PlantArcBio to develop resistant alfalfa » 08:45
06/16/21
06/16
08:45
06/16/21
08:45
BIOX

Bioceres

$12.00 /

-1.18 (-8.95%)

Bioceres announced a new…

Bioceres announced a new collaboration agreement with PlantArcBio, a gene discovery biotech company, for the development of improved biomass & drought tolerant Alfalfa, leveraging PlantArcBio's identified genes and Bioceres expertise in development of drought tolerant crops. In this collaboration, PlantArcBio has granted Bioceres the exclusive licensing rights to its biomass & drought resistance genes for Alfalfa worldwide; those genes were discovered by PlantArcBio. Bioceres will develop Alfalfa varieties incorporating those traits and will commercialize them. The agreement is contingent upon the successful incorporation of the genetic traits. Bioceres has developed a pipeline of alfalfa technologies currently at different stages of development, including drought tolerance, increased biomass and improved plant architecture. HB4 Alfalfa - drought tolerance - and different crop protection platforms are all entering regulatory stage. The global market for alfalfa hay is expected to grow at a CAGR of 5.89% to a market size of $20.6B in 2025, from $14.6B in 2019.

ShowHide Related Items >><<
BIOX Bioceres
$12.00 /

-1.18 (-8.95%)

BIOX Bioceres
$12.00 /

-1.18 (-8.95%)

04/08/21 Lake Street
Bioceres price target raised to $20 from $15 at Lake Street
03/15/21 Lake Street
Bioceres initiated with a Buy at Lake Street
BIOX Bioceres
$12.00 /

-1.18 (-8.95%)

BIOX Bioceres
$12.00 /

-1.18 (-8.95%)

BIOX Bioceres
$12.00 /

-1.18 (-8.95%)

Hot Stocks
BriaCell expands breast cancer platform technology into other cancers » 08:24
06/16/21
06/16
08:24
06/16/21
08:24
BCTX

BriaCell

$6.03 /

+0.51 (+9.24%)

BriaCell Therapeutics…

BriaCell Therapeutics announces the advancement of its targeted oncology therapeutics into several novel immunotherapy cell lines: Bria-Pros for prostate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer. BriaCell's immunotherapy treatment appeared most effective in breast cancer when the patient human leukocyte antigen molecules matched with the targeted immunotherapy, allowing BriaCell to potentially identify patients most likely to respond to the treatment. The novel approach uses an HLA-typing test - a simple and widely available test. BriaCell anticipates commencing clinical trials for these novel therapies in 2022. Bria-OTS in advanced breast cancer remains on track to commence patient dosing in 2021.

ShowHide Related Items >><<
BCTX BriaCell
$6.03 /

+0.51 (+9.24%)

  • 24
    Feb
Hot Stocks
SPI Energy subsidiary launches EV charging solutions in U.S. » 07:18
06/16/21
06/16
07:18
06/16/21
07:18
SPI

SPI Energy

$6.57 /

-0.19 (-2.81%)

SPI Energy announced its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SPI SPI Energy
$6.57 /

-0.19 (-2.81%)

  • 01
    Oct
SPI SPI Energy
$6.57 /

-0.19 (-2.81%)

SPI SPI Energy
$6.57 /

-0.19 (-2.81%)

Yesterday
Hot Stocks
Aptinyx says finalized design of Phase 2b program for NYX-783 in PTSD patients » 16:13
06/15/21
06/15
16:13
06/15/21
16:13
APTX

Aptinyx

$3.49 /

+ (+0.00%)

The analyst says:…

The analyst says: "Aptinyx announced that it has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder, or PTSD, after having received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration . The company expects to initiate the Phase 2b program in the fourth quarter of 2021. Aptinyx also announced that, in its preparation for Phase 2b, it identified a statistical error made by the contract research organization that performed the statistical analysis of the previously completed exploratory Phase 2 study in PTSD. Accordingly, the company is providing updated statistical analysis for the exploratory Phase 2 study, which has no impact on the study conclusions... In the process of completing its in-depth data analysis to prepare for and finalize the design of the Phase 2b program for NYX-783, the company identified a statistical modeling error made by the CRO that performed the statistical analysis of the previously completed exploratory Phase 2 study. The error resulted from an incorrect analysis of variance in the mixed model for repeated measures statistical model. While there were no changes to the numerical improvements from baseline, the revised MMRM p-values are higher than previously reported in October 2020. The CRO confirmed the error in late May and reported the updated statistical analysis to the company in June."

ShowHide Related Items >><<
APTX Aptinyx
$3.49 /

+ (+0.00%)

APTX Aptinyx
$3.49 /

+ (+0.00%)

01/29/21 JPMorgan
Aptinyx downgraded to Underweight from Neutral at JPMorgan
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
11/19/20 H.C. Wainwright
Aptinyx price target raised to $8 from $7 at H.C. Wainwright
11/12/20 Piper Sandler
Aptinyx pipeline catalysts on track, says Piper Sandler
APTX Aptinyx
$3.49 /

+ (+0.00%)

  • 22
    Oct
Monday
Options
Largest borrow rate increases among liquid names » 08:45
06/14/21
06/14
08:45
06/14/21
08:45
ARVL

Arrival

$19.20 /

-0.555 (-2.81%)

, UPST

Upstart

$125.55 /

-20.89 (-14.27%)

, HTZGQ

Hertz

$1.79 /

+ (+0.00%)

, IPOF

Social Capital Hedosophia Holdings Corp. VI

$10.33 /

+0.045 (+0.44%)

, ATER

Aterian

$15.81 /

+0.14 (+0.89%)

, PRPO

Precipio

$3.84 /

+0.04 (+1.05%)

, CLII

Climate Change Crisis Real Impact I

$13.70 /

-0.05 (-0.36%)

, SPI

SPI Energy

$6.95 /

-0.32 (-4.40%)

, LHDX

Lucira Health

$5.59 /

+0.29 (+5.47%)

, BNGO

Bionano Genomics

$7.57 /

-0.075 (-0.98%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Arrival (ARVL) 270.81% +107.38, Upstart Holdings (UPST) 83.44% +6.61, Hertz Global Holdings (HTZGQ) 20.53% +4.64, Social Capital Hedosophia VI (IPOF) 5.59% +3.93, Aterian (ATER) 14.66% +2.58, Precipio (PRPO) 37.93% +1.72, Climate Change Crisis Real Impact I Acquisition Corp (CLII) 16.84% +1.05, SPI Energy (SPI) 27.28% +0.41, Lucira Health (LHDX) 49.49% +0.39, and Bionano Genomics (BNGO) 1.96% +0.31.

ShowHide Related Items >><<
UPST Upstart
$125.55 /

-20.89 (-14.27%)

SPI SPI Energy
$6.95 /

-0.32 (-4.40%)

PRPO Precipio
$3.84 /

+0.04 (+1.05%)

LHDX Lucira Health
$5.59 /

+0.29 (+5.47%)

IPOF Social Capital Hedosophia Holdings Corp. VI
$10.33 /

+0.045 (+0.44%)

HTZGQ Hertz
$1.79 /

+ (+0.00%)

CLII Climate Change Crisis Real Impact I
$13.70 /

-0.05 (-0.36%)

BNGO Bionano Genomics
$7.57 /

-0.075 (-0.98%)

ATER Aterian
$15.81 /

+0.14 (+0.89%)

ARVL Arrival
$19.20 /

-0.555 (-2.81%)

ARVL Arrival
$19.20 /

-0.555 (-2.81%)

06/03/21 Barclays
Arrival initiated with an Overweight at Barclays
04/05/21 Cowen
Cowen starts Arrival at Outperform on 'unique microfactory approach'
04/05/21 Cowen
Arrival initiated with an Outperform at Cowen
UPST Upstart
$125.55 /

-20.89 (-14.27%)

05/12/21 JMP Securities
Upstart price target raised to $149 from $111 at JMP Securities
05/12/21 Piper Sandler
Upstart price target raised to $152 from $143 at Piper Sandler
04/27/21
Fly Intel: Top five analyst initiations
04/27/21 Piper Sandler
Upstart initiated with an Overweight at Piper Sandler
HTZGQ Hertz
$1.79 /

+ (+0.00%)

IPOF Social Capital Hedosophia Holdings Corp. VI
$10.33 /

+0.045 (+0.44%)

ATER Aterian
$15.81 /

+0.14 (+0.89%)

05/07/21 Alliance Global Partners
Alliance Global says Aterian stock oversold, calls a top pick after recent drop
05/05/21 Roth Capital
Aterian price target lowered to $30 from $40 at Roth Capital
PRPO Precipio
$3.84 /

+0.04 (+1.05%)

04/01/21 Maxim
Precipio price target raised to $7 from $2 at Maxim
CLII Climate Change Crisis Real Impact I
$13.70 /

-0.05 (-0.36%)

SPI SPI Energy
$6.95 /

-0.32 (-4.40%)

LHDX Lucira Health
$5.59 /

+0.29 (+5.47%)

05/04/21 William Blair
William Blair downgrades Lucira Health on slowing Covid testing volumes
05/04/21 William Blair
Lucira Health downgraded to Market Perform from Outperform at William Blair
04/13/21
Fly Intel: Top five analyst downgrades
04/13/21 BofA
Lucira Health downgraded to Underperform from Buy at BofA
BNGO Bionano Genomics
$7.57 /

-0.075 (-0.98%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
UPST Upstart
$125.55 /

-20.89 (-14.27%)

PRPO Precipio
$3.84 /

+0.04 (+1.05%)

LHDX Lucira Health
$5.59 /

+0.29 (+5.47%)

HTZGQ Hertz
$1.79 /

+ (+0.00%)

BNGO Bionano Genomics
$7.57 /

-0.075 (-0.98%)

  • 09
    Apr
  • 05
    Feb
  • 20
    Jan
  • 08
    Jan
  • 16
    Dec
  • 01
    Oct
IPOF Social Capital Hedosophia Holdings Corp. VI
$10.33 /

+0.045 (+0.44%)

HTZGQ Hertz
$1.79 /

+ (+0.00%)

CLII Climate Change Crisis Real Impact I
$13.70 /

-0.05 (-0.36%)

ARVL Arrival
$19.20 /

-0.555 (-2.81%)

UPST Upstart
$125.55 /

-20.89 (-14.27%)

SPI SPI Energy
$6.95 /

-0.32 (-4.40%)

LHDX Lucira Health
$5.59 /

+0.29 (+5.47%)

IPOF Social Capital Hedosophia Holdings Corp. VI
$10.33 /

+0.045 (+0.44%)

CLII Climate Change Crisis Real Impact I
$13.70 /

-0.05 (-0.36%)

BNGO Bionano Genomics
$7.57 /

-0.075 (-0.98%)

ARVL Arrival
$19.20 /

-0.555 (-2.81%)

UPST Upstart
$125.55 /

-20.89 (-14.27%)

SPI SPI Energy
$6.95 /

-0.32 (-4.40%)

PRPO Precipio
$3.84 /

+0.04 (+1.05%)

LHDX Lucira Health
$5.59 /

+0.29 (+5.47%)

IPOF Social Capital Hedosophia Holdings Corp. VI
$10.33 /

+0.045 (+0.44%)

HTZGQ Hertz
$1.79 /

+ (+0.00%)

CLII Climate Change Crisis Real Impact I
$13.70 /

-0.05 (-0.36%)

BNGO Bionano Genomics
$7.57 /

-0.075 (-0.98%)

ATER Aterian
$15.81 /

+0.14 (+0.89%)

ARVL Arrival
$19.20 /

-0.555 (-2.81%)

Hot Stocks
Safehold increases quarterly stock dividend by 4.8% to 17c per share » 07:36
06/14/21
06/14
07:36
06/14/21
07:36
SAFE

Safehold

$76.95 /

+0.65 (+0.85%)

Safehold announced that…

Safehold announced that the Company's Board of Directors has declared common stock dividends of 17c per share for the second quarter of 2021. The dividend represents an annualized rate of 68c per share and is payable on July 15 to holders of record on June 30.

ShowHide Related Items >><<
SAFE Safehold
$76.95 /

+0.65 (+0.85%)

SAFE Safehold
$76.95 /

+0.65 (+0.85%)

03/30/21 Goldman Sachs
Safehold price target lowered to $95 from $112 at Goldman Sachs
02/12/21 Mizuho
Safehold price target raised to $85 from $75 at Mizuho
01/27/21 Goldman Sachs
Safehold initiated with a Buy at Goldman Sachs
11/12/20 Mizuho
Safehold price target raised to $75 from $70 at Mizuho
SAFE Safehold
$76.95 /

+0.65 (+0.85%)

  • 11
    Nov
SAFE Safehold
$76.95 /

+0.65 (+0.85%)

Friday
Hot Stocks
Atossa Therapeutics approved by Swedish MPA to start phase 2 study on endoxifen » 09:05
06/11/21
06/11
09:05
06/11/21
09:05
ATOS

Atossa Therapeutics

$4.07 /

-0.34 (-7.72%)

Atossa Therapeutics…

Atossa Therapeutics announces that it has received approval from the Swedish Medical Product Agency, or MPA, to initiate a Phase 2 clinical study of its oral Endoxifen for the reduction of mammographic breast density, or MBD. The primary objective of the MBD study is to determine the dose-response relationship of daily oral Endoxifen on mammographic breast density reduction, with secondary endpoints assessing safety and tolerability. The Phase 2 study will be randomized, double-blinded and placebo-controlled. It will include approximately 240 pre-menopausal women with measurable MBD who will receive daily doses of oral Endoxifen or placebo for six months.

ShowHide Related Items >><<
ATOS Atossa Therapeutics
$4.07 /

-0.34 (-7.72%)

ATOS Atossa Therapeutics
$4.07 /

-0.34 (-7.72%)

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
ATOS Atossa Therapeutics
$4.07 /

-0.34 (-7.72%)

ATOS Atossa Therapeutics
$4.07 /

-0.34 (-7.72%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.